GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » EV-to-EBIT

PuraPharm (HKSE:01498) EV-to-EBIT : -101.01 (As of Jun. 01, 2025)


View and export this data going back to 2015. Start your Free Trial

What is PuraPharm EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PuraPharm's Enterprise Value is HK$548.5 Mil. PuraPharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-5.4 Mil. Therefore, PuraPharm's EV-to-EBIT for today is -101.01.

The historical rank and industry rank for PuraPharm's EV-to-EBIT or its related term are showing as below:

HKSE:01498' s EV-to-EBIT Range Over the Past 10 Years
Min: -108.29   Med: 10.22   Max: 45.7
Current: -100.65

During the past 11 years, the highest EV-to-EBIT of PuraPharm was 45.70. The lowest was -108.29. And the median was 10.22.

HKSE:01498's EV-to-EBIT is ranked worse than
100% of 688 companies
in the Drug Manufacturers industry
Industry Median: 17.055 vs HKSE:01498: -100.65

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. PuraPharm's Enterprise Value for the quarter that ended in Dec. 2024 was HK$568.2 Mil. PuraPharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-5.4 Mil. PuraPharm's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -0.96%.


PuraPharm EV-to-EBIT Historical Data

The historical data trend for PuraPharm's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PuraPharm EV-to-EBIT Chart

PuraPharm Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.46 -8.79 -9.83 -10.15 -104.65

PuraPharm Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.83 - -10.15 - -104.65

Competitive Comparison of PuraPharm's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PuraPharm's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PuraPharm's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PuraPharm's EV-to-EBIT falls into.


;
;

PuraPharm EV-to-EBIT Calculation

PuraPharm's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=548.491/-5.43
=-101.01

PuraPharm's current Enterprise Value is HK$548.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PuraPharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-5.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PuraPharm  (HKSE:01498) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

PuraPharm's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=-5.43/568.24415
=-0.96 %

PuraPharm's Enterprise Value for the quarter that ended in Dec. 2024 was HK$568.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PuraPharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-5.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PuraPharm EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of PuraPharm's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


PuraPharm Business Description

Traded in Other Exchanges
N/A
Address
Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG
PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing, and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. The organization provides Chinese medical diagnostic services and operates through several segments: China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation, and Clinics. The majority of its revenue comes from the Hong Kong CCMG segment, which mainly involves the sale of CCMG products, excluding sales through self-operated clinics in Hong Kong. The group derives revenue from customers located in Hong Kong, Mainland China, and Other countries.
Executives
Chan Yu Ling, Abraham 2101 Beneficial owner
Man Yee Wai, Viola 2202 Interest of your spouse
Fullgold Development Limited 2101 Beneficial owner

PuraPharm Headlines

No Headlines